BMS-790052

Gilead Bets on Hepatitis C Data to Back Pharmasset Deal
Bloomberg
Thu, 04/12/12 - 11:35 am
Gilead
hepatitis C
Pharmasset
BMS-790052
GS-7977
BMS-790052 Plus Peginterferon Alfa and Ribavirin Demonstrated up to 83% Sustained Virologic Response 24 Weeks Post-Treatment (SVR24) in Phase II Study of Genotype 1 Hepatitis C Patients
Yahoo/BusinessWire
Sun, 09/18/11 - 12:14 pm
Bristol-Myers Squibb
BMS-790052
Peginterferon Alfa
Ribavirin
hepatitis C
Bristol-Myers Presents HCV Data
Yahoo/Zacks
Sat, 04/2/11 - 10:29 am
Bristol-Myers Squibb
HCV
BMS-790052